argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more
argenx SE - Asset Resilience Ratio
argenx SE (ARGNF) has an Asset Resilience Ratio of 25.67% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how argenx SE's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down argenx SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.84 Billion | 25.67% |
| Total Liquid Assets | $1.84 Billion | 25.67% |
Asset Resilience Insights
- Very High Liquidity: argenx SE maintains exceptional liquid asset reserves at 25.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
argenx SE Industry Peers by Asset Resilience Ratio
Compare argenx SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for argenx SE (2014–2024)
The table below shows the annual Asset Resilience Ratio data for argenx SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 30.29% | $1.88 Billion | $6.20 Billion | +5.39pp |
| 2023-12-31 | 24.90% | $1.13 Billion | $4.54 Billion | -19.51pp |
| 2022-12-31 | 44.41% | $1.39 Billion | $3.13 Billion | +9.25pp |
| 2021-12-31 | 35.16% | $1.00 Billion | $2.85 Billion | +0.95pp |
| 2020-12-31 | 34.20% | $781.46 Million | $2.28 Billion | -35.88pp |
| 2019-12-31 | 70.08% | $1.00 Billion | $1.43 Billion | +21.07pp |
| 2018-12-31 | 49.01% | $283.53 Million | $578.46 Million | +3.48pp |
| 2017-12-31 | 45.54% | $168.91 Million | $370.91 Million | +39.08pp |
| 2016-12-31 | 6.46% | $6.83 Million | $105.77 Million | -8.36pp |
| 2015-12-31 | 14.82% | $6.81 Million | $45.96 Million | -25.84pp |
| 2014-12-31 | 40.66% | $23.79 Million | $58.51 Million | -- |